# The ROX@PDA@PCL vascularized bionic nerve conduit facilitates the restoration of nerve defects

**Authors:** Daoyi Lin, Jun Peng, Yichong Zhang, Xiaoping Wang, Xiaodong Xu, Jing Jia

PMC · DOI: 10.3389/fneur.2025.1561177 · Frontiers in Neurology · 2025-05-13

## TL;DR

A new vascularized nerve conduit was developed to improve nerve repair in rats by promoting blood vessel growth and enhancing nerve function recovery.

## Contribution

A novel vascularized bionic nerve conduit (ROX@PDA@PCL) was developed to enhance nerve repair through angiogenesis and functional recovery.

## Key findings

- ROX@PDA@PCL significantly enhanced angiogenesis and vascular endothelial cell proliferation in regenerated nerves.
- The conduit improved sciatic nerve functional recovery, approaching autologous graft outcomes in multiple metrics.
- Electrophysiological and histological assessments confirmed superior nerve regeneration compared to PDA@PCL and PCL groups.

## Abstract

Previous research has highlighted the pivotal role of angiogenesis in facilitating nerve function repair following nerve injury. In this study, we employed polydopamine (PDA) to modify polycaprolactone (PCL) and subsequently loaded it with roxadustat (ROX), thereby constructing a vascularized nerve conduit for the repair of a 10 mm sciatic nerve defect in rats. At 2 weeks post-surgery, new blood vessels were evaluated by immunofluorescence staining. Twelve weeks post-surgery, a comprehensive suite of assessments was conducted to evaluate the efficacy of the conduit, including gait analysis, determination of gastrocnemius muscle wet weight recovery, electrophysiological examination of gastrocnemius compound action potential (CMAP), Masson staining to evaluate gastrocnemius muscle fiber cross-sectional area, toluidine blue staining to assess the total number of regenerated myelinated nerve fibers, and electron microscopic observation of myelin sheath thickness. Our findings revealed that ROX@PDA@PCL could promote the proliferation of vascular endothelial cells and significantly enhance angiogenesis in regenerated nerves (p < 0.05). Regarding the recovery of neurological function, compared to the PDA@PCL and PCL groups, the ROX@PDA@PCL group exhibited significantly superior outcomes in the sciatic functional index (SFI), CMAP, gastrocnemius muscle wet weight ratio, muscle fiber cross-sectional area, total number of regenerated myelinated nerve fibers, and myelin sheath thickness. These indices approached those of the autologous group, but were still lower than in the autograft group (p < 0.05). The study underscores the potential of the vascularized nerve graft (ROX@PDA@PCL), constructed through PDA-mediated loading of ROX onto PCL, to enhance functional nerve recovery. Our findings present a promising new therapeutic approach for the clinical repair of peripheral nerve defects.

## Linked entities

- **Chemicals:** roxadustat (PubChem CID 11256664)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Diseases:** nerve defects (MESH:C537568), nerve injury (MESH:D000080902), peripheral nerve defects (MESH:D010523)
- **Chemicals:** ROX (MESH:C584543), Masson (-), PCL (MESH:C016240), PDA (MESH:C568283), toluidine blue (MESH:D014048)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12106018/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12106018/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12106018/full.md

---
Source: https://tomesphere.com/paper/PMC12106018